Browsing Tag
Abbott Laboratories
20 posts
Abbott adds colorectal cancer blood test to Cologuard portfolio after Freenome FDA win
Freenome wins FDA approval for SimpleScreen CRC, triggering a $100 million Abbott payment and setting up a fall U.S. launch.
Abbott (ABT) stock surges 12% as Q2 earnings beat lifts 2026 EPS outlook to $5.45-$5.60
Abbott shares headed for their strongest daily gain in 24 years after the healthcare group beat second-quarter expectations and raised its adjusted earnings forecast.
Catheter Precision (VTAK) rallies 122% on new patents and Flyte 1,000 user milestone
Catheter Precision (VTAK) rallies 122% as two new patents and Flyte hits 1,000 users boost pivot story. Going concern warning still shadows the rally.
Saluda Medical wins CAP24 FDA approval as ASX:SLD shares rally 22%
Discover how Saluda Medical’s CAP24 FDA approval may expand Evoke adoption, reshape SCS competition and test ASX’s execution. Read the analysis in full.
Why does Danaher (DHR) completing the Masimo acquisition matter for diagnostics and patient monitoring?
Find out how Danaher’s $9.9bn Masimo acquisition could reshape DHR’s diagnostics growth, medtech competition and investor sentiment.
Insulet Omnipod 6 data puts PODD back in focus as automated insulin delivery moves toward type 2 diabetes
Read how Insulet Omnipod 6 data could reshape automated insulin delivery, type 2 diabetes care and PODD stock sentiment. Find out what changes next in 2026.
DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market
Find out how DexCom’s CONNECT study could expand CGM use in non-insulin Type 2 diabetes and reshape DXCM’s growth outlook.
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?
What does Abbott’s Cancerguard AACR data mean for multi-cancer early detection and the $21bn Exact Sciences acquisition?
Abbott presents Cancerguard dual-biomarker MCED data at AACR 2026. What the DETECT-A survival findings mean for ABT, GRAIL, and cancer screening. Read more.
Is MiniMed (Nasdaq: MMED) worth watching after its IPO slide and before June earnings?
MiniMed (Nasdaq: MMED) is down from its IPO price. Read what June earnings, new product launches, and analyst targets could mean next.